JPMorgan Positive on Bristol-Myers Squibb Co. (BMY): 'We Expect Strong Uptake Mid2025 and Beyond'
Tweet Send to a Friend
JPMorgan analyst Chris Schott reiterated an Overweight rating and $60.00 price target on Bristol-Myers Squibb Co. (NYSE: BMY)The analyst comments ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
